Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
THE OPPORTUNITY Adobe is looking for a leader to analyze, structure, and continuously improve our Product-Led Growth (PLG) workstreams — aligning them with Adobes operating model while protecting the speed, autonomy, and data-driven decision culture that